TuHURA Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-30.62	-30.05	-21.68	-29.32	-9.37
Depreciation & Amortization	0.1	0.07	0.12	0.18	0.37
Other Amortization	0.78	0.48	1.28	0.01	-
Asset Writedown & Restructuring Costs	-	-	-	16.22	-
Loss (Gain) From Sale of Investments	-1.59	-1.59	-	-	-
Stock-Based Compensation	8.53	6.42	1.96	0.48	0.22
Other Operating Activities	0.19	0.19	0.31	-	-0.29
Change in Accounts Payable	-7.72	-3.76	3.64	0.34	1.85
Change in Other Net Operating Assets	0.66	0.61	-0.36	0.15	-0.29
Operating Cash Flow	-29.69	-27.63	-14.73	-11.95	-7.51
Operating Cash Flow Growth	-	-	-	-	-
Capital Expenditures	-0.21	-0.08	-0.06	-1.3	-0.04
Cash Acquisitions	-	-1.26	-5.99	-	-
Investing Cash Flow	-0.21	-1.34	-6.05	-1.3	-0.04
Short-Term Debt Issued	-	3	-	-	-
Long-Term Debt Issued	-	-	28.57	2.69	-
Total Debt Issued	6.6	3	28.57	2.69	-
Short-Term Debt Repaid	-	-2.33	-	-	-
Long-Term Debt Repaid	-	-0.05	-	-	-0.35
Total Debt Repaid	-2.6	-2.38	-	-	-0.35
Net Debt Issued (Repaid)	4	0.62	28.57	2.69	-0.35
Issuance of Common Stock	20.2	21.92	7.05	-	-
Repurchase of Common Stock	-	-	-	-0.02	-
Preferred Dividends Paid	-0.01	-0.01	-	-	-
Dividends Paid	-0.01	-0.01	-	-	-
Other Financing Activities	-1.8	-2.61	-5.84	-	-
Financing Cash Flow	22.39	19.93	29.77	2.66	16.25
Net Cash Flow	-7.52	-9.04	8.99	-10.59	8.71
Free Cash Flow	-29.9	-27.71	-14.79	-13.25	-7.54
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Per Share	-0.53	-0.58	-0.79	-1.11	-
Levered Free Cash Flow	-22.32	-4.76	-14.91	-8.29	-
Unlevered Free Cash Flow	-22.39	-4.85	-13.6	-8.29	-
Cash Interest Paid	0.06	0.06	-	-	-
Change in Working Capital	-7.06	-3.15	3.29	0.49	1.56

SEC Filings: 10-K · 10-Q